Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Leap Therapeutics, Inc. (LPTX) had Return on Tangible Equity of -291.11% for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-16.64M |
|
-- |
|
-- |
|
$16.88M |
|
$-16.88M |
|
$0.24M |
|
$-16.64M |
|
$-16.64M |
|
$-16.64M |
|
$-16.64M |
|
$-16.64M |
|
$-16.64M |
|
$-16.88M |
|
$-16.88M |
|
41.45M |
|
41.45M |
|
$-0.40 |
|
$-0.40 |
|
| Balance Sheet Financials | |
$19.16M |
|
-- |
|
$0.88M |
|
$20.04M |
|
$14.32M |
|
-- |
|
-- |
|
$14.32M |
|
$5.72M |
|
$5.72M |
|
$5.72M |
|
41.44M |
|
| Cash Flow Statement Financials | |
$-28.97M |
|
-- |
|
$-0.18M |
|
$47.25M |
|
$18.13M |
|
$-29.12M |
|
$2.69M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.34 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-28.97M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-291.12% |
|
|
Return on Tangible Equity |
-291.11% |
-83.04% |
|
-291.11% |
|
$0.14 |
|
$-0.70 |
|
$-0.70 |
|